ARTICLE | Product Development
Galapagos gains on Phase II win for systemic sclerosis candidate
September 12, 2020 1:35 AM UTC
Galapagos’ investors rewarded a clinical win on Friday for ziritaxestat, which met its primary endpoint in the Phase IIa NOVESA trial in patients with cutaneous systemic sclerosis.
The company gained €7.55 (7%) to €115.50 on Euronext and $11.05 (9%) to $136.85 on NASDAQ Friday after reporting the ENPP2 inhibitor led to an -8.3 change from baseline on the modified Rodnan Skin Score (mRSS) at week 24 vs. -5.7 for placebo (p=0.0411). Detailed data will be presented at a future medical meeting...